1.. I[NTRODUCTION]{.smallcaps}
==============================

Cancer is a genetic disease arising when mutations of genes provide sufficient growth advantage to induce neoplastic transformation. For example, the p14^arf^ and p16^ink4a^ proteins coded from the CDKN2A tumor suppressor gene locus regulate RB1 and p53, controlling cell cycle and apoptosis, respectively. Homozygous deletion of this locus removes such control, promoting cell division and providing a selective advantage towards cancer. Tumor suppressor genes can also be inactivated by small single nucleotide mutations, such as p53 and PTEN, for example. The mutation inactivates 1 allele, and hemizygous deletion can remove the other allele to achieve functional inactivation. This results in loss of homozygosity (LOH) across the loci. Conversely, genomic amplification of ERBB2 contributes to uncontrolled positive growth signaling. The copy number status of cancer genes can serve as prognostic markers in various cancer types and, as in the case of ERBB2, can constitute an effective target for therapy. It is therefore imperative to be able to accurately assess cancer genomes for copy number changes and to accurately analyze this data taking into account the full information content available. Given that genotypes enable sample identification, microarrays offer an all encompassing solution.

These platforms perform genotyping experiments across millions of single nucleotide polymorphisms (SNPs) simultaneously, which produce copy number information in addition to SNP genotypes. Microarray technologies have a proven record for investigating genetic disease. For example, oligonucleotide microarrays produce both genotypes applied to genome-wide association studies ([@bib35]) and to analyze population copy number variation (CNV) ([@bib21]). These methods have also been successfully applied to examine CNV in cancers ([@bib5]; [@bib34]). Modern platforms such as the affymetrix genome-wide SNP6.0 platform contain additional nonpolymorphic probes, designed to give greater genomic resolution of copy number in regions of lower SNP density. Alternative technologies such as molecular inversion probes (MIPs) ([@bib31]) and SNP bead arrays (Collela *and others*, 2007; [@bib33]; [@bib23]) have similarly been used and produce allelic ratios that can be used to infer "allelic" copy number. All these platforms require algorithms to infer these features.

Methods to extract copy number segmentation range from circular binary segmentation to hierarchical clustering ([@bib12]; [@bib15], [@bib14]; [@bib18]; [@bib19]; [@bib20]; [@bib22]; [@bib27]; [@bib37]). Hidden Markov models (HMMs) have proven to be a particularly powerful tool in this field ([@bib4]; [@bib7]; [@bib8]; [@bib16]; [@bib28]; [@bib29]; [@bib30]) and have been used to identify LOH in addition to copy number segmentation. A comparison of various methods can be found in [@bib3].

There are also a variety of methods by which SNP genotypes are classified ([@bib1]; [@bib2]; [@bib6]; [@bib9]; [@bib17]; [@bib11]; [@bib24]; [@bib36]).

Increasingly, methods are offering more integrated approaches to the 3-fold problem of estimating total copy number across the genome, finding the allelic ratio of segments, and identifying the true genotype of SNPs. These include the VanillaICE package from [@bib28] that takes SNP data consisting of copy number intensities and genotypes (classified as heterozygous or homozygous) and implement an HMM. The states are designed to capture trends in copy number and do not resolve copy number into its allelic integer components. However, it is a generic method for SNP data requiring no training data that is quick to implement only requiring data from a single sample. The mixed model approach of Wang, [@bib6] harnesses patterns of genotype clustering across multiple samples with a mixed model approach to infer both allelic copy number and genotype at individual SNPs. The calculations are done on a per SNP basis and treat consecutive SNPs independently. Accurate segmentation and break-point estimation will require smoothing (such as with an HMM), which can be critical in cancer studies when it is desirable to know if a particular break point is disrupting a gene\'s function, for example. The PennCNV ([@bib31]) and Birdsuite packages ([@bib13]) are the most comprehensive, providing allelic copy number and genotype inference for illumina SNP bead arrays and the affymetrix genome-wide SNP6.0 arrays, respectively.

This work considers the problems that arise when cancer data is analyzed using these methods and discusses bespoke techniques that may be applied to circumvent these issues. Specifically, cancer is frequency aneuploid in nature, which causes a systematic bias in preprocessing techniques utilized by these methods. This can also result in the misalignment of copy number states with these algorithms. This problem is explored in more detail in Section 2. We then introduce preprocessing and segmentation techniques suitable for cancer data. This method is validated using the affymetrix genome-wide SNP6.0 platform upon 460 wild-type and 755 cancer samples using a range of independent validation methods. A discussion completes the paper.

2.. C[ANCER ASSOCIATED BIASES]{.smallcaps}
==========================================

Cancer samples are known to commonly exhibit aneuploidy ([@bib26]) with many quadraploid and triploid samples, for example. Such variable ploidy affects the preprocessing used in such algorithms. More specifically, when seeding DNA to a microarray plate, the quantity is controlled by fixing the mass of DNA used. For noncancerous samples, cells in different samples have very similar amounts of DNA (i.e. from a diploid genome). A constant mass of DNA then effectively fixes the number of cells in each well on the plate, and the signals derived from each SNP allele are directly proportional to the allelic copy number for all samples. These signals are sensitive enough to distinguish allelic differences as seen in [Figure 1(A)](#fig1){ref-type="fig"}, where the allelic intensities for a single SNP across a set of 461 normals clearly cluster according to the 3 wild-type genotype classes AA, AB, and BB. Such a structure is required for both Birdsuite and the mixed model approach of Wang, [@bib6]. For example, Birdsuite correctly identified the heterozygous state across a sample of 108 cancer samples genotyped in only 70.13% of cases when compared to cDNA genotypes, far lower than figures reported using benchmarking with wild-type cells.

![Allelic intensities for a single SNP across multiple samples. (A) The A allele intensity is plotted against the B allele intensity for each wild-type training sample at a single polymorphic probe. The MAP estimates of the linearly separated mean allelic intensities for genotypes AA, AB, and BB are indicated in red. (B) The same allelic intensities are plotted using the cancer samples. The significant reduction in clustering is evident.](biostskxp045f01_4c){#fig1}

Because the DNA delivered to each well in a microarray plate is controlled by total mass, a quadraploid sample will have half the number of cells seeded than a diploid sample. If 2 such samples have a region of identical copy number, then wells designed to hybridize within this region will produce half the signal in the quadraploid sample than from the diploid sample. In particular, the signal is no longer proportional to copy number, which will produce biases in any inference making this assumption. This adversely affects the clustering of the allelic copy number intensities by genotype. [Figure 1(B)](#fig1){ref-type="fig"} displays the allelic intensities for the same SNP as [Figure 1(A)](#fig1){ref-type="fig"} across a series of cancers, where the clustering is clearly compromised. Although this effect could in theory be corrected by incorporating the ploidy of the cancer, this is usually not *a priori* knowledge and would require spectral karyotyping (SKY) or flow sorting the samples to control the total number of cells.

The deviations in ploidy are readily observed via SKY. For example, using cancer cell line samples HCC1806 (diploid), HCC1187 (triploid), and ZR-75-30 (quadraploid), the average copy number of each chromosome was calculated using SKY ([@bib10]), and using Birdsuite upon SNP6.0 array data. The results can be seen in [Figure 2](#fig2){ref-type="fig"} (and [Supplementary Figure 2](http://biostatistics.oxfordjournals.org/cgi/content/full/kxp045/DC1), available at *Biostatistics* online) where Birdsuite does not capture differences in ploidy revealed by SKY.

![Genome-wide copy number estimates of diploid, triploid, and quadraploid samples HCC1806, HCC1187, and ZR-75-30, respectively. Copy number estimates are obtained using SKY (dashed), Birdsuite (red), and PICNIC (green).](biostskxp045f02_4c){#fig2}

These data show that although current integrative methods such as those of [@bib28], Wang, [@bib6] and [@bib13] work well for integrated copy number analyses in wild-type cells, these methods are less applicable to cancer samples and exhibit greatest error where the ploidy departs from normal. A bespoke preprocessing procedure that captures the departure from the normal clustering seen in [Figure 1(B), and a](#fig1){ref-type="fig"} segmentation routine that can calibrate to unusual ploidy, and ultimately provide accurate integrated allelic copy number and genotyping analyses in cancer, is thus desirable.

To this end, we next introduce the 2 stage procedure predict integral copy numbers in cancer (PICNIC). We first introduce a preprocessing step that utilizes the genotype structure observed by others (Wang, [@bib6]; [@bib13]) in normal tissues to convert the raw cancer data into copy number and genotype intensities. We then introduce a Bayesian HMM to identify segments of fixed integer allelic copy number using the data produced by the preprocessing step. We also use the model to classify the SNPs into their complex cancer genotypes.

3.. C[ANCER BESPOKE METHODS]{.smallcaps}
========================================

The preprocessing is essentially composed of 2 steps; a microarray plate correction and a normalization step. The segmentation step then follows.

Across the sample set, the total probe intensity from each array varies substantially due to different running times and conditions in the experimental process. In order to reduce this "microarray plate" variation, we simply dividing all intensities by the total microarray signal from each sample.

The normalization step is a correction for the probe variation observed in [Figure 1(B)](#fig1){ref-type="fig"}. We first need to gain an understanding of the wild-type behavior at each probe. This is achieved by fitting a mixture of bivariate normal distribution to the 3 clusters observed in [Figure 1(A)](#fig1){ref-type="fig"}. A Bayesian approach helps with this fitting where the clustering structure is less clear with less informative SNPs. This results in maximum *a priori* (MAP) estimates (*A*~*g*~, *B*~*g*~) representing the mean cluster positions corresponding to genotypes *g* ∈ {*AA*, *AB*, *BB*}. These are assumed to align linearly so that,

We next utilized this information to transform cancer data into a copy number intensity *r*~*ct*~ and a genotype intensity ϑ~*ct*~. We would like any point (*x*~*ct*~^*A*^, *x*~*ct*~^*B*^) on the line passing through the 3 genotype clusters to have a copy number intensity of unity. We first linearly transform the intensities to map clusters AA, AB, and BB to mean positions (1,3), (2,2), and (3,1), and map the residual intensity loci (*A*~0~, *B*~0~) to (1,1). The genotype intensity ϑ~*ct*~ is then defined to be the (normalized) angle from the origin to the transformed cancer intensities. We then define transformation,

This completes the preprocessing. Examples can be seen in [Figures 3(A) and (B)](#fig3){ref-type="fig"}, where copy number and genotype intensities for genomic regions of cancer cell line HCC1187 are displayed. The combination of copy number and genotype intensities clearly reveal the full range of allelic copy numbers present in the samples.

![Absolute copy number, genotype intensity, and break-point likelihoods for cancer cell lines HCC1187. Each plot contains 3 sections. First are copy number intensities, followed by genotype intensities. Associated genotypes are indicated. Green and blue lines indicate total and minor estimated copy number. Black and red lines represent heterozygous and homozygous segments. Finally, the likelihoods of state change are plotted. The horizontal scale is genomic position in megabases. Vertical scales represent chromosomal copy number. (A and B) derive from chromosomes 14 and 19, respectively.](biostskxp045f03_4c){#fig3}

The final step involves the segmentation and genotyping of the data, which was achieved using a Bayesian HMM. Such methods have previously been successfully applied to allelic copy number such as with PennCNV and Birdsuite. The states used tend to encompass a large range of genotypes observed in genetic disease. However, cancer does not exhibit such a wide range, and the HMM requires a specific copy number state space relevant to cancer. Specifically, prior to the formation of a somatic copy number variant, there is 1 copy of each parental wild-type segment, and the genotypes of the SNPs within the region are AA, AB, or BB. After the copy number variant is formed, the segment contains *g* and *h* − *g* copies of each parental segment (*h* segments in total), ordered such that *g* ≤ *h* − *g*. Here, *g* and *h* − *g* denote the "minor" and "major" copy numbers, respectively. For a segment of the genome of fixed total copy number *h*, there are possible copy number states, indexed by . For each state pair (*g*, *h*), we get 4 genotypes; {A × *h*}, {A ×(*h* − *g*), B × *g*}, {A × *g*, B ×(*h* − *g*)}, or {B × *h*}. These genotypes can coincide where LOH is present (*g* = 0) or we have an even number of chromosomes (*g* = *h*/2). This results in between 1 and 4 possible genotypes within a segment of copy number state (*g*,*h*). This information is summarized in [Table 1](#tbl1){ref-type="table"}, examples of which can be seen in [Figure 3](#fig3){ref-type="fig"}.

###### 

Genotype classes by copy number states. A description of possible genotypes for the first few minor and major copy numbers

  Total copy number (*h*)   Number of genotype classes   Number of minor alleles (*g*) 0 (LOH)   1                            2
  ------------------------- ---------------------------- --------------------------------------- ---------------------------- ----------------------------
  0                         1                            DEL                                     --                           --
  1                         1                            {A,B}                                   --                           --
  2                         2                            {AA,BB}                                 {AA,AB,BB}                   --
  3                         2                            {AAA,BBB}                               {AAA,AAB,ABB,BBB}            --
  4                         3                            {AAAA,BBBB}                             {AAAA,AAAB,ABBB,BBBB}        {AAAA,AABB,BBBB}
  5                         3                            {AAAAA,BBBBB}                           {AAAAA,AAAAB, ABBBB,BBBBB}   {AAAAA,AAABB, AABBB,BBBBB}

The Bayesian HMM was fitted with the Baum--Welch algorithm and segmented with the Viterbi algorithm ([@bib25]). This process is sensitive to the initial seeding of the parameters, which requires a heuristic approach to accurately calibrate copy number with copy number intensity. The forward--backward equations can then be used to infer several features of interest including genotype classification and to associate confidence to break-point estimates. Full details of these methods can be found in [Supplementary Text 1](http://biostatistics.oxfordjournals.org/cgi/content/full/kxp045/DC1), available at *Biostatistics* online.

4.. V[ALIDATION]{.smallcaps}
============================

In order to assess performance, we examined the HMM\'s prediction of deletions, LOH, amplifications, break points, copy number estimation, and genotyping using cancer cell lines cultured from a variety of tissue types. We also benchmarked these results against Birdsuite. These are considered below and summarized in [Table 2](#tbl2){ref-type="table"}. Further details can be found in [Supplementary Table 1](http://biostatistics.oxfordjournals.org/cgi/content/full/kxp045/DC1), available at *Biostatistics* online.

###### 

Validation methods. Results are summarized for validation of homozygous deletions, genotypes, LOH, copy number, break points, and amplifications. Statistics used include true positive and false positive rates (TPR, FPR), the percentage of correct calls and the mean error

  Data type              Validation set                      Test set                Statistic    PICNIC           Birdsuite
  ---------------------- ----------------------------------- ----------------------- ------------ ---------------- ----------------
  Copy number            SKY                                 HCC1806(diploid)        \% Correct   65.35%           59.83%
  Copy number            SKY                                 HCC1187(triploid)       \% Correct   80.56%           52.55%
  Copy number            SKY                                 ZR-75-30(quadraploid)   \% Correct   77.67%           6.43%
  Homozygous deletions   confirmatory PCR for 7 known TSGs   102 cell lines          TPR (FPR)    77.55% (0.15%)   59.18% (0.15%)
  Genotypes              cDNA hom genotyping                 108 cell lines          \% Correct   96.45%           70.13%
  LOH                    400 microsatellite markers          755 cell lines          TPR (FPR)    58.20% (5.34%)   NA
  Break points           SKY                                 HCC1806(diploid)        TPR          55.41%           56.76%
  Break points           SKY                                 HCC1187(triploid)       TPR          46.81%           48.94%
  Break points           SKY                                 ZR-75-30(quadraploid)   TPR          75.51%           63.27%
  Amplicons              qPCR of GLO1 amplified cluster      58 cell lines           Mean error   5.44%            11.51%

The predicted copy number of PICNIC and Birdsuite was assessed by comparing results to copy numbers obtained using SKY ([@bib10]). This was determined for HCC1806 (diploid), HCC1187 (triploid), and ZR-75-30 (quadraploid). The genomic extent (Mb) of correctly and incorrectly predicted copy numbers were then determined, giving 65.35%, 80.56%, and 77.67% for PICNIC, respectively. The values for Birdsuite are 59.83%, 52.55%, and 6.43%, respectively. Although results for the diploid sample are similar, the improvement for the more complex genomes using the cancer specific software is clear, as can be seen in [Figure 2](#fig2){ref-type="fig"}. We also used the break points estimated by [@bib10] in these 3 samples to determine how many were detected using PICNIC and Birdsuite. PICNIC identified 55.41%, 46.81%, and 75.51%, and Birdsuite was comparible identifying 56.76%, 48.94%, and 63.27%, respectively.

To investigate specificity and sensitivity of deletion detection, 7 known tumor suppressor genes (CDKN2C, CDKN2A, PTEN, RB1, MAP2K4, SMAD4, and STK11) were screened for the presence of deletions using PICNIC and Birdsuite. The same genes were also screened using multiplex polymerase chain reaction (PCR) with a probe per exon. These 2 independent methods were then compared across 102 cell lines. A total of 38/49 (77.55%) deletions were detected by PICNIC, showing excellent sensitivity and specificity. This reduces to 59.18% for Birdsuite.

In order to test the performance of LOH prediction, the repeat lengths of both alleles of approximately 400 microsatellite markers are derived. As both alleles derive from a wide choice of counts, an identical pair of repeat lengths is indicative of LOH and was designated as so. The HMM LOH status at each marker was compared to the microsatellite LOH status. Excellent specificity was shown, with only 4989/93410 (5.34%) markers with 2 distinct microsatellite repeat lengths being identified as LOH by PICNIC. Although sensitivity was lower, with 40970/70391 (58.2%) agreement, this is consistent with the rate that markers produced identical repeat length alleles (32.7% from normal samples). Segmental LOH status could not be obtained from Birdsuite.

To test the performance of amplification prediction, quantitative PCR (qPCR) with 20 probes was implemented comparing the copy number of a commonly amplified gene cluster containing GLO1 to the reference control gene β-actin. The relative copy number of this cluster to the reference gene was also calculated from the predicted copy number states for both methods and results compared. The average relative copy number across this region differed from qPCR by 5.44% and 11.51% using PICNIC and Birdsuite, respectively.

PICNIC provides genotype likelihoods for all polymorphic probes. Maximum likelihood was then used to determine whether the probe was heterozygous or specify the homozygous allele. To validate the classifications, cDNA of 20 probes were genotyped across 108 cell lines. A total of 1406/1448 (97.10%) homozygous SNPs were correctly identified as homozygous and 441/467 (94.43%) as heterozygous. These figures drop to 78.12% and 45.27%, respectively, for Birdsuite.

In summary, although using generalized copy number software upon cancer data can lead to systematic errors which are most apparent with anueploid genomes, techniques bespoke to tumor data, such as PICNIC, provide an effective means by which these biases can be overcome and provide accurate information regarding allelic integer copy number and genotype information in cancer.

5.. D[ISCUSSION]{.smallcaps}
============================

Methods to investigate the genotypes and CNV in tumor samples are an important component of cancer genomics. Although oligonucleotide platforms such as affymetrix genome-wide SNP6.0 arrays have been successfully applied to wild-type genetics with integrative algorithms such as VanillaICE, that of Wang, [@bib6], and Birdsuite, the aneuploid nature of cancer produces biases that require more bespoke methods. We have introduced an algorithm that successfully caters for these effects. These techniques allow a complete portrait of integral allelic copy number in cancer to be derived for the full range of aneuploidy observed in cancer.

This process (PICNIC) was implemented with a training set of 461 normal samples and 755 cancer cell lines from a wide spectrum of tissue types and histologies using data obtained through affymetrix genome-wide SNP6.0 array technology and implemented with Matlab. The method was shown to accurately predict integer major and minor copy numbers, complex cancer genotypes, homozygous deletion, amplification, and regions of LOH with good break-point accuracy. This allows detection of subtle changes such as copy neutral LOH and hemizygous deletion providing a more complete profile of CNV in cancer genomes.

The preprocessing training steps were implemented using 461 normal samples and took approximately 3 Ghz × 100 h computing time to complete for the affymetrix genome-wide SNP 6.0 array. This step only needs to be done once and the renormalization can then be implemented quickly on many samples. The segmentation step was implemented for the 1216 wild-type and cancer samples in approximately 3 Ghz × 3 h running time per sample (a multinode farm was used in application), with a maximum segmented copy number of 15. This time could be reduced by dropping either the maximum segmented copy number or dropping the Baum--Welch optimization and just using Viterbi segmentation with seeded parameters. The running time scales linearly with the number of samples and the number of probes but scales quadratically with the maximum segmented copy number.

Data quality was occasionally compromised due to various factors. Experimental protocols or conditions could produce noisy data, readily fixed by optimization, or repeat runs. Contaminated samples produce spurious results, [Supplementary Figure 1](http://biostatistics.oxfordjournals.org/cgi/content/full/kxp045/DC1), available at *Biostatistics* online exhibiting a putative example, but such cases can be resourced. Although cell lines are typically composed of a single outgrown clone, there is some evidence that cell lines occasionally contain multiple subclones with different copy numbers in different genomic regions. Regions that contain distinct copy number by clone will likely produce unexpected (nonintegral) copy number intensities. Such mosaicism provides a difficult problem for the entire field of CNV in cancer. Chromosome 11 of sample HCC1187 is a probable example of this (see [Figure 1(B)](#fig1){ref-type="fig"} in [Supplementary Text 1](http://biostatistics.oxfordjournals.org/cgi/content/full/kxp045/DC1), available at *Biostatistics* online), where the mean copy number intensity for this chromosome is between the mean values associated with copy numbers of 3 and 4). Genotype intensities were also affected, reproducing the mean signal from all present clones. Finally, we note that this algorithm has only been applied to cell lines, and that primary samples with normal tissue contamination or containing multiple dominant clones may not segment as well. We note that the preprocessing step is suitable for all samples, however, irrespective of any mosaicism or normal contamination that may be present.

These experiments have produced a significant volume of invaluable data, aiding the identification of candidate tumor suppressor genes, oncogenes, and gene fusions. The segmented data of all analyzed samples can be viewed at <http://www.sanger.ac.uk/cgi-bin/genetics/CGP/cghviewer/CghHome.cgi>. The raw data (\*.cel files) are an open resource available at www.sanger.ac.uk/genetics/CGP/Archive/. The algorithm was coded in (UNIX) Matlab and both the preprocessing and segmentation algorithms are available under a free Berkeley software distribution license from www.sanger.ac.uk/genetics/CGP/Software/.

S[UPPLEMENTARY MATERIAL]{.smallcaps}
====================================

[Supplementary material](http://biostatistics.oxfordjournals.org/cgi/content/full/kxp045/DC1) is available at <http://biostatistics.oxfordjournals.org>.
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